In considering Ca2+ signaling proteins as therapeutic targets in the prevention and treatment of HCC, it is useful to summarize the mutations and altered expression of Ca2+ signaling proteins so far detected in HCC in the human liver. This evidence concerns the gene PROS1 and hepatocellular carcinoma.